← All Passage Bio, INC filings

Passage Bio, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
PASG
Passage Bio, INC
10-K: Passage Bio's 2025 10-K: Gene Therapy Progress Amidst Losses
Passage Bio reports continued operating losses in its 2025 annual filing, advancing its lead gene therapy candidate PBFT02 for neurodegenerative diseases while navigating financial and operational challenges.
NASDAQ
PASG
Passage Bio, INC
10-K: Passage Bio Reports 2024 Results, Outlines Strategy for PBFT02 Development
Passage Bio focuses on PBFT02 development for neurodegenerative diseases after out-licensing pediatric programs.
NASDAQ
PASG
Passage Bio, INC
10-K: Passage Bio 10-K Filing: Strategic Shift and Focus on Neurodegenerative Diseases
Passage Bio's 10-K filing highlights a strategic shift towards neurodegenerative diseases, prioritizing PBFT02 development and exploring out-licensing opportunities for pediatric programs.